USPTO serial 87914539
GEOMX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- RATCLIFFE, ROBERT L
- Law office
- TMO LAW OFFICE 130 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with GEOMX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Alyssa Worsham
Alyssa Worsham WILSON SONSINI GOODRICH & ROSATI650 PAGE MILL ROADPALO ALTO, CA 94304-1050UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | diagnostic reagents and instruments for medical or veterinary use in the fields of pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; diagnostic reagents for medical or veterinary use in the fields of cancer, neurology and infectious disease; diagnostic reagent kits comprising primarily of diagnostic reagents for medical or veterinary use in the fields of cancer, neurology and infectious disease; chemical reagents for medical use; reagents for medical or veterinary use containing antibodies and nucleic acids; diagnostic test kits for medical use comprising primarily reagents, slides, solid matrix materials, microfluidic devices sold as a unit with instructional manuals therefor; medical or veterinary diagnostic kits comprising medical or veterinary diagnostic reagents for use in detecting the presence of analytes in samples and identifying sample type, and equipment, namely, medical diagnostic immuno-assays for screening samples detecting the presence of analytes in samples and identifying sample type, sold as a unit with instructional manuals; diagnostic preparations in the nature of antibodies, for medical and veterinary purposes; reagents and diagnostic reagents for medical or veterinary purposes; diagnostic preparations in the nature of in situ hybridization probes, for medical and veterinary purposes; medical or veterinary diagnostic reagents for pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; multiparameter quantitative detection and analysis products and technology for diagnostics for a variety of uses in health care, namely, pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; medical diagnostic reagents and assays for testing of body fluids or tissue; kits consisting primarily of medical or veterinary diagnostic reagents and assays for testing of body fluids or tissue; reagents in the form of cell markers and molecule markers including antibodies and nucleic acids for medical or veterinary purposes; medical diagnostic reagents for use in the fields of pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; medical diagnostic reagents for use relating to molecular identification and digital quantification; medical diagnostic reagents containing antibodies and nucleic acids; medical diagnostic reagents for use in the fields of cancer, neurology and infectious disease; medical diagnostic reagents for immuno-histochemistry detection and in situ-hybridization detection; medical diagnostic reagents for use relating to molecular identification and digital quantification | ACTIVE | Sep 5, 2018 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 16, 2022 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jun 16, 2022 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Dec 3, 2021 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 3, 2021 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 3, 2021 | CNRT | SU - NON-FINAL ACTION - WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 30, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 19, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 17, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 16, 2021 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Aug 16, 2021 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Aug 5, 2021 | IUAF | USE AMENDMENT FILED | — |
| Aug 5, 2021 | EXT5 | SOU EXTENSION 5 FILED | — |
| Aug 5, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 5, 2021 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Jan 22, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 20, 2021 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Jan 20, 2021 | EXT4 | SOU EXTENSION 4 FILED | — |
| Jan 20, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 22, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 20, 2020 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Jul 20, 2020 | EXT3 | SOU EXTENSION 3 FILED | — |
| Jul 20, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 1, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 30, 2020 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jan 30, 2020 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jan 30, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 29, 2019 | NOAC | CORRECTED NOA E-MAILED | — |
| Oct 28, 2019 | DPCC | DIVISIONAL PROCESSING COMPLETE | — |
| Oct 25, 2019 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Oct 23, 2019 | DRRR | DIVISIONAL REQUEST RECEIVED | — |
| Oct 23, 2019 | ERTD | TEAS REQUEST TO DIVIDE RECEIVED | — |
| Oct 3, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 2, 2019 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Oct 2, 2019 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Aug 15, 2019 | NREV | NOTICE OF REVIVAL - E-MAILED | — |
| Aug 15, 2019 | TPEX | SOU EXTENSION RECEIVED WITH TEAS PETITION | — |
| Aug 15, 2019 | PETG | PETITION TO REVIVE-GRANTED | — |
| Aug 15, 2019 | PROA | TEAS PETITION TO REVIVE RECEIVED | — |
| Aug 5, 2019 | EXT1 | SOU EXTENSION 1 FILED | — |
| Feb 5, 2019 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Dec 11, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 11, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 21, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 2, 2018 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Nov 2, 2018 | ALIE | ASSIGNED TO LIE | — |
| Oct 18, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 15, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 14, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 14, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 31, 2018 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Aug 31, 2018 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Aug 31, 2018 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Aug 30, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| May 18, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 12, 2018 | NWAP | NEW APPLICATION ENTERED | — |